Tag Archives: possible

#437673 Can AI and Automation Deliver a COVID-19 ...

Illustration: Marysia Machulska

Within moments of meeting each other at a conference last year, Nathan Collins and Yann Gaston-Mathé began devising a plan to work together. Gaston-Mathé runs a startup that applies automated software to the design of new drug candidates. Collins leads a team that uses an automated chemistry platform to synthesize new drug candidates.

“There was an obvious synergy between their technology and ours,” recalls Gaston-Mathé, CEO and cofounder of Paris-based Iktos.

In late 2019, the pair launched a project to create a brand-new antiviral drug that would block a specific protein exploited by influenza viruses. Then the COVID-19 pandemic erupted across the world stage, and Gaston-Mathé and Collins learned that the viral culprit, SARS-CoV-2, relied on a protein that was 97 percent similar to their influenza protein. The partners pivoted.

Their companies are just two of hundreds of biotech firms eager to overhaul the drug-discovery process, often with the aid of artificial intelligence (AI) tools. The first set of antiviral drugs to treat COVID-19 will likely come from sifting through existing drugs. Remdesivir, for example, was originally developed to treat Ebola, and it has been shown to speed the recovery of hospitalized COVID-19 patients. But a drug made for one condition often has side effects and limited potency when applied to another. If researchers can produce an ­antiviral that specifically targets SARS-CoV-2, the drug would likely be safer and more effective than a repurposed drug.

There’s one big problem: Traditional drug discovery is far too slow to react to a pandemic. Designing a drug from scratch typically takes three to five years—and that’s before human clinical trials. “Our goal, with the combination of AI and automation, is to reduce that down to six months or less,” says Collins, who is chief strategy officer at SRI Biosciences, a division of the Silicon Valley research nonprofit SRI International. “We want to get this to be very, very fast.”

That sentiment is shared by small biotech firms and big pharmaceutical companies alike, many of which are now ramping up automated technologies backed by supercomputing power to predict, design, and test new antivirals—for this pandemic as well as the next—with unprecedented speed and scope.

“The entire industry is embracing these tools,” says Kara Carter, president of the International Society for Antiviral Research and executive vice president of infectious disease at Evotec, a drug-discovery company in Hamburg. “Not only do we need [new antivirals] to treat the SARS-CoV-2 infection in the population, which is probably here to stay, but we’ll also need them to treat future agents that arrive.”

There are currentlyabout 200 known viruses that infect humans. Although viruses represent less than 14 percent of all known human pathogens, they make up two-thirds of all new human pathogens discovered since 1980.

Antiviral drugs are fundamentally different from vaccines, which teach a person’s immune system to mount a defense against a viral invader, and antibody treatments, which enhance the body’s immune response. By contrast, anti­virals are chemical compounds that directly block a virus after a person has become infected. They do this by binding to specific proteins and preventing them from functioning, so that the virus cannot copy itself or enter or exit a cell.

The SARS-CoV-2 virus has an estimated 25 to 29 proteins, but not all of them are suitable drug targets. Researchers are investigating, among other targets, the virus’s exterior spike protein, which binds to a receptor on a human cell; two scissorlike enzymes, called proteases, that cut up long strings of viral proteins into functional pieces inside the cell; and a polymerase complex that makes the cell churn out copies of the virus’s genetic material, in the form of single-stranded RNA.

But it’s not enough for a drug candidate to simply attach to a target protein. Chemists also consider how tightly the compound binds to its target, whether it binds to other things as well, how quickly it metabolizes in the body, and so on. A drug candidate may have 10 to 20 such objectives. “Very often those objectives can appear to be anticorrelated or contradictory with each other,” says Gaston-Mathé.

Compared with antibiotics, antiviral drug discovery has proceeded at a snail’s pace. Scientists advanced from isolating the first antibacterial molecules in 1910 to developing an arsenal of powerful antibiotics by 1944. By contrast, it took until 1951 for researchers to be able to routinely grow large amounts of virus particles in cells in a dish, a breakthrough that earned the inventors a Nobel Prize in Medicine in 1954.

And the lag between the discovery of a virus and the creation of a treatment can be heartbreaking. According to the World Health Organization, 71 million people worldwide have chronic hepatitis C, a major cause of liver cancer. The virus that causes the infection was discovered in 1989, but effective antiviral drugs didn’t hit the market until 2014.

While many antibiotics work on a range of microbes, most antivirals are highly specific to a single virus—what those in the business call “one bug, one drug.” It takes a detailed understanding of a virus to develop an antiviral against it, says Che Colpitts, a virologist at Queen’s University, in Canada, who works on antivirals against RNA viruses. “When a new virus emerges, like SARS-CoV-2, we’re at a big disadvantage.”

Making drugs to stop viruses is hard for three main reasons. First, viruses are the Spartans of the pathogen world: They’re frugal, brutal, and expert at evading the human immune system. About 20 to 250 nanometers in diameter, viruses rely on just a few parts to operate, hijacking host cells to reproduce and often destroying those cells upon departure. They employ tricks to camouflage their presence from the host’s immune system, including preventing infected cells from sending out molecular distress beacons. “Viruses are really small, so they only have a few components, so there’s not that many drug targets available to start with,” says Colpitts.

Second, viruses replicate quickly, typically doubling in number in hours or days. This constant copying of their genetic material enables viruses to evolve quickly, producing mutations able to sidestep drug effects. The virus that causes AIDS soon develops resistance when exposed to a single drug. That’s why a cocktail of antiviral drugs is used to treat HIV infection.

Finally, unlike bacteria, which can exist independently outside human cells, viruses invade human cells to propagate, so any drug designed to eliminate a virus needs to spare the host cell. A drug that fails to distinguish between a virus and a cell can cause serious side effects. “Discriminating between the two is really quite difficult,” says Evotec’s Carter, who has worked in antiviral drug discovery for over three decades.

And then there’s the money barrier. Developing antivirals is rarely profitable. Health-policy researchers at the London School of Economics recently estimated that the average cost of developing a new drug is US $1 billion, and up to $2.8 billion for cancer and other specialty drugs. Because antivirals are usually taken for only short periods of time or during short outbreaks of disease, companies rarely recoup what they spent developing the drug, much less turn a profit, says Carter.

To change the status quo, drug discovery needs fresh approaches that leverage new technologies, rather than incremental improvements, says Christian Tidona, managing director of BioMed X, an independent research institute in Heidelberg, Germany. “We need breakthroughs.”

Putting Drug Development on Autopilot
Earlier this year, SRI Biosciences and Iktos began collaborating on a way to use artificial intelligence and automated chemistry to rapidly identify new drugs to target the COVID-19 virus. Within four months, they had designed and synthesized a first round of antiviral candidates. Here’s how they’re doing it.

1/5

STEP 1: Iktos’s AI platform uses deep-learning algorithms in an iterative process to come up with new molecular structures likely to bind to and disable a specific coronavirus protein. Illustrations: Chris Philpot

2/5

STEP 2: SRI Biosciences’s SynFini system is a three-part automated chemistry suite for producing new compounds. Starting with a target compound from Iktos, SynRoute uses machine learning to analyze and optimize routes for creating that compound, with results in about 10 seconds. It prioritizes routes based on cost, likelihood of success, and ease of implementation.

3/5

STEP 3: SynJet, an automated inkjet printer platform, tests the routes by printing out tiny quantities of chemical ingredients to see how they react. If the right compound is produced, the platform tests it.

4/5

STEP 4: AutoSyn, an automated tabletop chemical plant, synthesizes milligrams to grams of the desired compound for further testing. Computer-selected “maps” dictate paths through the plant’s modular components.

5/5

STEP 5: The most promising compounds are tested against live virus samples.

Previous
Next

Iktos’s AI platform was created by a medicinal chemist and an AI expert. To tackle SARS-CoV-2, the company used generative models—deep-learning algorithms that generate new data—to “imagine” molecular structures with a good chance of disabling a key coronavirus protein.

For a new drug target, the software proposes and evaluates roughly 1 million compounds, says Gaston-Mathé. It’s an iterative process: At each step, the system generates 100 virtual compounds, which are tested in silico with predictive models to see how closely they meet the objectives. The test results are then used to design the next batch of compounds. “It’s like we have a very, very fast chemist who is designing compounds, testing compounds, getting back the data, then designing another batch of compounds,” he says.

The computer isn’t as smart as a human chemist, Gaston-Mathé notes, but it’s much faster, so it can explore far more of what people in the field call “chemical space”—the set of all possible organic compounds. Unexplored chemical space is huge: Biochemists estimate that there are at least 1063 possible druglike molecules, and that 99.9 percent of all possible small molecules or compounds have never been synthesized.

Still, designing a chemical compound isn’t the hardest part of creating a new drug. After a drug candidate is designed, it must be synthesized, and the highly manual process for synthesizing a new chemical hasn’t changed much in 200 years. It can take days to plan a synthesis process and then months to years to optimize it for manufacture.

That’s why Gaston-Mathé was eager to send Iktos’s AI-generated designs to Collins’s team at SRI Biosciences. With $13.8 million from the Defense Advanced Research Projects Agency, SRI Biosciences spent the last four years automating the synthesis process. The company’s automated suite of three technologies, called SynFini, can produce new chemical compounds in just hours or days, says Collins.

First, machine-learning software devises possible routes for making a desired molecule. Next, an inkjet printer platform tests the routes by printing out and mixing tiny quantities of chemical ingredients to see how they react with one another; if the right compound is produced, the platform runs tests on it. Finally, a tabletop chemical plant synthesizes milligrams to grams of the desired compound.

Less than four months after Iktos and SRI Biosciences announced their collaboration, they had designed and synthesized a first round of antiviral candidates for SARS-CoV-2. Now they’re testing how well the compounds work on actual samples of the virus.

Out of 10
63 possible druglike molecules, 99.9 percent have never been synthesized.

Theirs isn’t the only collaborationapplying new tools to drug discovery. In late March, Alex Zhavoronkov, CEO of Hong Kong–based Insilico Medicine, came across a YouTube video showing three virtual-reality avatars positioning colorful, sticklike fragments in the side of a bulbous blue protein. The three researchers were using VR to explore how compounds might bind to a SARS-CoV-2 enzyme. Zhavoronkov contacted the startup that created the simulation—Nanome, in San Diego—and invited it to examine Insilico’s ­AI-generated molecules in virtual reality.

Insilico runs an AI platform that uses biological data to train deep-learning algorithms, then uses those algorithms to identify molecules with druglike features that will likely bind to a protein target. A four-day training sprint in late January yielded 100 molecules that appear to bind to an important SARS-CoV-2 protease. The company recently began synthesizing some of those molecules for laboratory testing.

Nanome’s VR software, meanwhile, allows researchers to import a molecular structure, then view and manipulate it on the scale of individual atoms. Like human chess players who use computer programs to explore potential moves, chemists can use VR to predict how to make molecules more druglike, says Nanome CEO Steve McCloskey. “The tighter the interface between the human and the computer, the more information goes both ways,” he says.

Zhavoronkov sent data about several of Insilico’s compounds to Nanome, which re-created them in VR. Nanome’s chemist demonstrated chemical tweaks to potentially improve each compound. “It was a very good experience,” says Zhavoronkov.

Meanwhile, in March, Takeda Pharmaceutical Co., of Japan, invited Schrödinger, a New York–based company that develops chemical-simulation software, to join an alliance working on antivirals. Schrödinger’s AI focuses on the physics of how proteins interact with small molecules and one another.

The software sifts through billions of molecules per week to predict a compound’s properties, and it optimizes for multiple desired properties simultaneously, says Karen Akinsanya, chief biomedical scientist and head of discovery R&D at Schrödinger. “There’s a huge sense of urgency here to come up with a potent molecule, but also to come up with molecules that are going to be well tolerated” by the body, she says. Drug developers are seeking compounds that can be broadly used and easily administered, such as an oral drug rather than an intravenous drug, she adds.

Schrödinger evaluated four protein targets and performed virtual screens for two of them, a computing-intensive process. In June, Google Cloud donated the equivalent of 16 million hours of Nvidia GPU time for the company’s calculations. Next, the alliance’s drug companies will synthesize and test the most promising compounds identified by the virtual screens.

Other companies, including Amazon Web Services, IBM, and Intel, as well as several U.S. national labs are also donating time and resources to the Covid-19 High Performance Computing Consortium. The consortium is supporting 87 projects, which now have access to 6.8 million CPU cores, 50,000 GPUs, and 600 petaflops of computational resources.

While advanced technologies could transform early drug discovery, any new drug candidate still has a long road after that. It must be tested in animals, manufactured in large batches for clinical trials, then tested in a series of trials that, for antivirals, lasts an average of seven years.

In May, the BioMed X Institute in Germany launched a five-year project to build a Rapid Antiviral Response Platform, which would speed drug discovery all the way through manufacturing for clinical trials. The €40 million ($47 million) project, backed by drug companies, will identify ­outside-the-box proposals from young scientists, then provide space and funding to develop their ideas.

“We’ll focus on technologies that allow us to go from identification of a new virus to 10,000 doses of a novel potential therapeutic ready for trials in less than six months,” says BioMed X’s Tidona, who leads the project.

While a vaccine will likely arrive long before a bespoke antiviral does, experts expect COVID-19 to be with us for a long time, so the effort to develop a direct-acting, potent antiviral continues. Plus, having new antivirals—and tools to rapidly create more—can only help us prepare for the next pandemic, whether it comes next month or in another 102 years.

“We’ve got to start thinking differently about how to be more responsive to these kinds of threats,” says Collins. “It’s pushing us out of our comfort zones.”

This article appears in the October 2020 print issue as “Automating Antivirals.” Continue reading

Posted in Human Robots

#437639 Boston Dynamics’ Spot Is Helping ...

In terms of places where you absolutely want a robot to go instead of you, what remains of the utterly destroyed Chernobyl Reactor 4 should be very near the top of your list. The reactor, which suffered a catastrophic meltdown in 1986, has been covered up in almost every way possible in an effort to keep its nuclear core contained. But eventually, that nuclear material is going to have to be dealt with somehow, and in order to do that, it’s important to understand which bits of it are just really bad, and which bits are the actual worst. And this is where Spot is stepping in to help.

The big open space that Spot is walking through is right next to what’s left of Reactor 4. Within six months of the disaster, Reactor 4 was covered in a sarcophagus made of concrete and steel to try and keep all the nasty nuclear fuel from leaking out more than it already had, and it still contains “30 tons of highly contaminated dust, 16 tons of uranium and plutonium, and 200 tons of radioactive lava.” Oof. Over the next 10 years, the sarcophagus slowly deteriorated, and despite the addition of that gigantic network of steel support beams that you can see in the video, in the late 1990s it was decided to erect an enormous building over the entire mess to try and stabilize it for as long as possible.

Reactor 4 is now snugly inside the massive New Safe Confinement (NSC) structure, and the idea is that eventually, the structure will allow for the safe disassembly of what’s left of the reactor, although nobody is quite sure how to do that. This is all just to say that the area inside of the containment structure offers a lot of good opportunities for robots to take over from humans.

This particular Spot is owned by the U.K. Atomic Energy Authority, and was packed off to Russia with the assistance of the Robotics and Artificial Intelligence in Nuclear (RAIN) initiative and the National Centre for Nuclear Robotics. Dr. Dave Megson-Smith, who is a researcher at the University of Bristol, in the U.K., and part of the Hot Robotics Facility at the National Nuclear User Facility, was one of the scientists lucky enough to accompany Spot on its adventure. Megson-Smith specializes in sensor development, and he equipped Spot with a collimated radiation sensor in addition to its mapping payload. “We actually built a map of the radiation coming out of the front wall of Chernobyl power plant as we were in there with it,” Megson-Smith told us, and was able to share this picture, which shows a map of gamma photon count rate:

Image: University of Bristol

Researchers equipped Spot with a collimated radiation sensor and use one of the data readings (gamma photon count rate) to create a map of the radiation coming out of the front wall of the Chernobyl power plant.

So what’s the reason you’d want to use a very expensive legged robot to wander around what looks like a very flat and robot friendly floor? As it turns out, the floor is very dusty in there, and a priority inside the NSC is to keep dust down as much as possible, since the dust is radioactive and gets on everything and is consequently the easiest way for radioactivity to escape the NSC. “You want to minimize picking up material, so we consider the total contact surface area,” says Megson-Smith. “If you use a legged system rather than a wheeled or tracked system, you have a much smaller footprint and you disturb the environment a lot less.” While it’s nice that Spot is nimble and can climb stairs and stuff, tracked vehicles can do that as well, so in this case, the primary driving factor of choosing a robot to work inside Chernobyl is minimizing those contact points.

Right now, routine weekly measurements in contaminated spaces at Chernobyl are done by humans, which puts those humans at risk. Spot, or a robot like it, could potentially take over from those humans, as a sort of “automated safety checker”

Right now, routine weekly measurements in contaminated spaces at Chernobyl are done by humans, which puts those humans at risk. Spot, or a robot like it, could potentially take over from those humans, as a sort of “automated safety checker” able to work in medium level contaminated environments.” As far as more dangerous areas go, there’s a lot of uncertainty about what Spot is actually capable of, according to Megson-Smith. “What you think the problems are, and what the industry thinks the problems are, are subtly different things.

We were thinking that we’d have to make robots incredibly radiation proof to go into these contaminated environments, but they said, “can you just give us a system that we can send into places where humans already can go, but where we just don’t want to send humans.” Making robots incredibly radiation proof is challenging, and without extensive testing and ruggedizing, failures can be frequent, as many robots discovered at Fukushima. Indeed, Megson-Smith that in Fukushima there’s a particular section that’s known as a “robot graveyard” where robots just go to die, and they’ve had to up their standards again and again to keep the robots from failing. “So the thing they’re worried about with Spot is, what is its tolerance? What components will fail, and what can we do to harden it?” he says. “We’re approaching Boston Dynamics at the moment to see if they’ll work with us to address some of those questions.

There’s been a small amount of testing of how robots fair under harsh radiation, Megson-Smith told us, including (relatively recently) a KUKA LBR800 arm, which “stopped operating after a large radiation dose of 164.55(±1.09) Gy to its end effector, and the component causing the failure was an optical encoder.” And in case you’re wondering how much radiation that is, a 1 to 2 Gy dose to the entire body gets you acute radiation sickness and possibly death, while 8 Gy is usually just straight-up death. The goal here is not to kill robots (I mean, it sort of is), but as Megson-Smith says, “if we can work out what the weak points are in a robotic system, can we address those, can we redesign those, or at least understand when they might start to fail?” Now all he has to do is convince Boston Dynamics to send them a Spot that they can zap until it keels over.

The goal for Spot in the short term is fully autonomous radiation mapping, which seems very possible. It’ll also get tested with a wider range of sensor packages, and (happily for the robot) this will all take place safely back at home in the U.K. As far as Chernobyl is concerned, robots will likely have a substantial role to play in the near future. “Ultimately, Chernobyl has to be taken apart and decommissioned. That’s the long-term plan for the facility. To do that, you first need to understand everything, which is where we come in with our sensor systems and robotic platforms,” Megson-Smith tells us. “Since there are entire swathes of the Chernobyl nuclear plant where people can’t go in, we’d need robots like Spot to do those environmental characterizations.” Continue reading

Posted in Human Robots

#437630 How Toyota Research Envisions the Future ...

Yesterday, the Toyota Research Institute (TRI) showed off some of the projects that it’s been working on recently, including a ceiling-mounted robot that could one day help us with household chores. That system is just one example of how TRI envisions the future of robotics and artificial intelligence. As TRI CEO Gill Pratt told us, the company is focusing on robotics and AI technology for “amplifying, rather than replacing, human beings.” In other words, Toyota wants to develop robots not for convenience or to do our jobs for us, but rather to allow people to continue to live and work independently even as we age.

To better understand Toyota’s vision of robotics 15 to 20 years from now, it’s worth watching the 20-minute video below, which depicts various scenarios “where the application of robotic capabilities is enabling members of an aging society to live full and independent lives in spite of the challenges that getting older brings.” It’s a long video, but it helps explains TRI’s perspective on how robots will collaborate with humans in our daily lives over the next couple of decades.

Those are some interesting conceptual telepresence-controlled bipeds they’ve got running around in that video, right?

For more details, we sent TRI some questions on how it plans to go from concepts like the ones shown in the video to real products that can be deployed in human environments. Below are answers from TRI CEO Gill Pratt, who is also chief scientist for Toyota Motor Corp.; Steffi Paepcke, senior UX designer at TRI; and Max Bajracharya, VP of robotics at TRI.

IEEE Spectrum: TRI seems to have a more explicit focus on eventual commercialization than most of the robotics research that we cover. At what point TRI starts to think about things like reliability and cost?

Photo: TRI

Toyota is exploring robots capable of manipulating dishes in a sink and a dishwasher, performing experiments and simulations to make sure that the robots can handle a wide range of conditions.

Gill Pratt: It’s a really interesting question, because the normal way to think about this would be to say, well, both reliability and cost are product development tasks. But actually, we need to think about it at the earliest possible stage with research as well. The hardware that we use in the laboratory for doing experiments, we don’t worry about cost there, or not nearly as much as you’d worry about for a product. However, in terms of what research we do, we very much have to think about, is it possible (if the research is successful) for it to end up in a product that has a reasonable cost. Because if a customer can’t afford what we come up with, maybe it has some academic value but it’s not actually going to make a difference in their quality of life in the real world. So we think about cost very much from the beginning.

The same is true with reliability. Right now, we’re working very hard to make our control techniques robust to wide variations in the environment. For instance, in work that Russ Tedrake is doing with manipulating dishes in a sink and a dishwasher, both in physical testing and in simulation, we’re doing thousands and now millions of different experiments to make sure that we can handle the edge cases and it works over a very wide range of conditions.

A tremendous amount of work that we do is trying to bring robotics out of the age of doing demonstrations. There’s been a history of robotics where for some time, things have not been reliable, so we’d catch the robot succeeding just once and then show that video to the world, and people would get the mis-impression that it worked all of the time. Some researchers have been very good about showing the blooper reel too, to show that some of the time, robots don’t work.

“A tremendous amount of work that we do is trying to bring robotics out of the age of doing demonstrations. There’s been a history of robotics where for some time, things have not been reliable, so we’d catch the robot succeeding just once and then show that video to the world, and people would get the mis-impression that it worked all of the time.”
—Gill Pratt, TRI

In the spirit of sharing things that didn’t work, can you tell us a bit about some of the robots that TRI has had under development that didn’t make it into the demo yesterday because they were abandoned along the way?

Steffi Paepcke: We’re really looking at how we can connect people; it can be hard to stay in touch and see our loved ones as much as we would like to. There have been a few prototypes that we’ve worked on that had to be put on the shelf, at least for the time being. We were exploring how to use light so that people could be ambiently aware of one another across distances. I was very excited about that—the internal name was “glowing orb.” For a variety of reasons, it didn’t work out, but it was really fascinating to investigate different modalities for keeping in touch.

Another prototype we worked on—we found through our research that grocery shopping is obviously an important part of life, and for a lot of older adults, it’s not necessarily the right answer to always have groceries delivered. Getting up and getting out of the house keeps you physically active, and a lot of people prefer to continue doing it themselves. But it can be challenging, especially if you’re purchasing heavy items that you need to transport. We had a prototype that assisted with grocery shopping, but when we pivoted our focus to Japan, we found that the inside of a Japanese home really needs to stay inside, and the outside needs to stay outside, so a robot that traverses both domains is probably not the right fit for a Japanese audience, and those were some really valuable lessons for us.

Photo: TRI

Toyota recently demonstrated a gantry robot that would hang from the ceiling to perform tasks like wiping surfaces and clearing clutter.

I love that TRI is exploring things like the gantry robot both in terms of near-term research and as part of its long-term vision, but is a robot like this actually worth pursuing? Or more generally, what’s the right way to compromise between making an environment robot friendly, and asking humans to make changes to their homes?

Max Bajracharya: We think a lot about the problems that we’re trying to address in a holistic way. We don’t want to just give people a robot, and assume that they’re not going to change anything about their lifestyle. We have a lot of evidence from people who use automated vacuum cleaners that people will adapt to the tools you give them, and they’ll change their lifestyle. So we want to think about what is that trade between changing the environment, and giving people robotic assistance and tools.

We certainly think that there are ways to make the gantry system plausible. The one you saw today is obviously a prototype and does require significant infrastructure. If we’re going to retrofit a home, that isn’t going to be the way to do it. But we still feel like we’re very much in the prototype phase, where we’re trying to understand whether this is worth it to be able to bypass navigation challenges, and coming up with the pros and cons of the gantry system. We’re evaluating whether we think this is the right approach to solving the problem.

To what extent do you think humans should be either directly or indirectly in the loop with home and service robots?

Bajracharya: Our goal is to amplify people, so achieving this is going to require robots to be in a loop with people in some form. One thing we have learned is that using people in a slow loop with robots, such as teaching them or helping them when they make mistakes, gives a robot an important advantage over one that has to do everything perfectly 100 percent of the time. In unstructured human environments, robots are going to encounter corner cases, and are going to need to learn to adapt. People will likely play an important role in helping the robots learn. Continue reading

Posted in Human Robots

#437620 The Trillion-Transistor Chip That Just ...

The history of computer chips is a thrilling tale of extreme miniaturization.

The smaller, the better is a trend that’s given birth to the digital world as we know it. So, why on earth would you want to reverse course and make chips a lot bigger? Well, while there’s no particularly good reason to have a chip the size of an iPad in an iPad, such a chip may prove to be genius for more specific uses, like artificial intelligence or simulations of the physical world.

At least, that’s what Cerebras, the maker of the biggest computer chip in the world, is hoping.

The Cerebras Wafer-Scale Engine is massive any way you slice it. The chip is 8.5 inches to a side and houses 1.2 trillion transistors. The next biggest chip, NVIDIA’s A100 GPU, measures an inch to a side and has a mere 54 billion transistors. The former is new, largely untested and, so far, one-of-a-kind. The latter is well-loved, mass-produced, and has taken over the world of AI and supercomputing in the last decade.

So can Goliath flip the script on David? Cerebras is on a mission to find out.

Big Chips Beyond AI
When Cerebras first came out of stealth last year, the company said it could significantly speed up the training of deep learning models.

Since then, the WSE has made its way into a handful of supercomputing labs, where the company’s customers are putting it through its paces. One of those labs, the National Energy Technology Laboratory, is looking to see what it can do beyond AI.

So, in a recent trial, researchers pitted the chip—which is housed in an all-in-one system about the size of a dorm room mini-fridge called the CS-1—against a supercomputer in a fluid dynamics simulation. Simulating the movement of fluids is a common supercomputer application useful for solving complex problems like weather forecasting and airplane wing design.

The trial was described in a preprint paper written by a team led by Cerebras’s Michael James and NETL’s Dirk Van Essendelft and presented at the supercomputing conference SC20 this week. The team said the CS-1 completed a simulation of combustion in a power plant roughly 200 times faster than it took the Joule 2.0 supercomputer to do a similar task.

The CS-1 was actually faster-than-real-time. As Cerebrus wrote in a blog post, “It can tell you what is going to happen in the future faster than the laws of physics produce the same result.”

The researchers said the CS-1’s performance couldn’t be matched by any number of CPUs and GPUs. And CEO and cofounder Andrew Feldman told VentureBeat that would be true “no matter how large the supercomputer is.” At a point, scaling a supercomputer like Joule no longer produces better results in this kind of problem. That’s why Joule’s simulation speed peaked at 16,384 cores, a fraction of its total 86,400 cores.

A comparison of the two machines drives the point home. Joule is the 81st fastest supercomputer in the world, takes up dozens of server racks, consumes up to 450 kilowatts of power, and required tens of millions of dollars to build. The CS-1, by comparison, fits in a third of a server rack, consumes 20 kilowatts of power, and sells for a few million dollars.

While the task is niche (but useful) and the problem well-suited to the CS-1, it’s still a pretty stunning result. So how’d they pull it off? It’s all in the design.

Cut the Commute
Computer chips begin life on a big piece of silicon called a wafer. Multiple chips are etched onto the same wafer and then the wafer is cut into individual chips. While the WSE is also etched onto a silicon wafer, the wafer is left intact as a single, operating unit. This wafer-scale chip contains almost 400,000 processing cores. Each core is connected to its own dedicated memory and its four neighboring cores.

Putting that many cores on a single chip and giving them their own memory is why the WSE is bigger; it’s also why, in this case, it’s better.

Most large-scale computing tasks depend on massively parallel processing. Researchers distribute the task among hundreds or thousands of chips. The chips need to work in concert, so they’re in constant communication, shuttling information back and forth. A similar process takes place within each chip, as information moves between processor cores, which are doing the calculations, and shared memory to store the results.

It’s a little like an old-timey company that does all its business on paper.

The company uses couriers to send and collect documents from other branches and archives across town. The couriers know the best routes through the city, but the trips take some minimum amount of time determined by the distance between the branches and archives, the courier’s top speed, and how many other couriers are on the road. In short, distance and traffic slow things down.

Now, imagine the company builds a brand new gleaming skyscraper. Every branch is moved into the new building and every worker gets a small filing cabinet in their office to store documents. Now any document they need can be stored and retrieved in the time it takes to step across the office or down the hall to their neighbor’s office. The information commute has all but disappeared. Everything’s in the same house.

Cerebras’s megachip is a bit like that skyscraper. The way it shuttles information—aided further by its specially tailored compiling software—is far more efficient compared to a traditional supercomputer that needs to network a ton of traditional chips.

Simulating the World as It Unfolds
It’s worth noting the chip can only handle problems small enough to fit on the wafer. But such problems may have quite practical applications because of the machine’s ability to do high-fidelity simulation in real-time. The authors note, for example, the machine should in theory be able to accurately simulate the air flow around a helicopter trying to land on a flight deck and semi-automate the process—something not possible with traditional chips.

Another opportunity, they note, would be to use a simulation as input to train a neural network also residing on the chip. In an intriguing and related example, a Caltech machine learning technique recently proved to be 1,000 times faster at solving the same kind of partial differential equations at play here to simulate fluid dynamics.

They also note that improvements in the chip (and others like it, should they arrive) will push back the limits of what can be accomplished. Already, Cerebras has teased the release of its next-generation chip, which will have 2.6 trillion transistors, 850,00 cores, and more than double the memory.

Of course, it still remains to be seen whether wafer-scale computing really takes off. The idea has been around for decades, but Cerebras is the first to pursue it seriously. Clearly, they believe they’ve solved the problem in a way that’s useful and economical.

Other new architectures are also being pursued in the lab. Memristor-based neuromorphic chips, for example, mimic the brain by putting processing and memory into individual transistor-like components. And of course, quantum computers are in a separate lane, but tackle similar problems.

It could be that one of these technologies eventually rises to rule them all. Or, and this seems just as likely, computing may splinter into a bizarre quilt of radical chips, all stitched together to make the most of each depending on the situation.

Image credit: Cerebras Continue reading

Posted in Human Robots

#437616 Innovative YUJIN 3D LiDAR, Now Shipping!

Recently Yujin Robot launched a new 3D LiDAR for indoor service robot, AGVs/AMRs and smart factory. The YRL3 series is a line of precise laser sensors for vertical and horizontal scanning to detect environments or objects. The Yujin Robot YRL3 series LiDAR is designed for indoor applications and utilizes an innovative 3D scanning LiDAR for a 270°(Horizontal) x 90°(vertical) dynamic field of view as a single channel. The fundamental principle is based on direct ToF (Time of Flight) and designed to measure distances towards surroundings. YRL3 collect useful data including ranges, angles, intensities and Cartesian coordinates (x,y,z). Real-time vertical right-angle adjustment is possible and supports powerful S/W package for autonomous driving devices.

“In recent years, our product lineup expanded to include models for the Fourth Industrial Revolution,” shares the marketing team of Yujin Robot. These models namely are Kobuki, the ROS reference research robot platform used by robotics research labs around the world, the Yujin LiDAR range-finding scanning sensor for LiDAR-based autonomous driving, AMS solution (Autonomous Mobility Solution) for customized autonomous driving. The company continues to push the boundaries of robotics and artificial intelligence, developing game-changing autonomous solutions that give companies around the world an edge over the competition.

Photo: Yujin

YUJIN 3D LiDAR, Now Shipping! Indoor 3D LiDAR for AGVs/AMRs, Service Robots, and Factories Continue reading

Posted in Human Robots